Presentation on theme: "“Current and Future Trends in Jobs for Veterinary Pathologists” Co-Chairs: Drs. Jon Werner (Amgen) and Kevin Lahmers (Washington St. Univ) Panelists: Drs."— Presentation transcript:
“Current and Future Trends in Jobs for Veterinary Pathologists” Co-Chairs: Drs. Jon Werner (Amgen) and Kevin Lahmers (Washington St. Univ) Panelists: Drs. Chris Clarke (Amgen), John Cullen (NC St Univ), Kevin Keane (Consultant), Kevin Lahmers, Charles Wood (EPA), and Aaron Sargeant (CRL) 1
Introduction (5 min) Brief statements from panelists (20 min) ◦ Please hold questions Open discussion (35 min) ◦ Before talking, please ID yourself Continued discussion over cocktails 2
3 Paraphrased opinion from Terry Leyden from the Leyden Group, a private recruiting firm in toxicology for over 30 years, and supporter of the ACVP/STP coalition: Through 2008, there was a healthy job market for early career pathologists. Since that time, this market has virtually disappeared due to: ◦ Large and mid sized pharma reducing staff and small biotech lacking funding. ◦ CROs having work volume drop, and sufficient staffing. ◦ Experienced pathologists leaving industry and offering consulting services. However, there will be a large number of experienced pathologists retiring soon - "brain drain". Companies should consider succession planning.
NCSU Davis/Penn Hiring level empty positions filled No new positions created Qualifications PhD generally required High level of competition Lots of good diagnosticians available Desirables Research training/program High level of competition Vet Schools contracting slightly due to state funding issues Some new positions available, but… Need to have the right niche Specialized diagnostic skills Research program Tox path depends on regional support Hiring in Academia Dr. John Cullen, NC State
In the past year, there has been a significant uptick in jobs posted There are a lot of people looking Do things to help yourself stand out ◦ Boards ◦ PhD ◦ Teaching experience ◦ Specialize-to an extent It is currently largely about fit in the current buyer’s market
Qualifications – DVM, DACVP, PhD….. ◦ DABT, MD Experience – drug discovery and development ◦ Discovery science – peer engagement ◦ Tox Path – characterization, interpretation, risk assessment ◦ Drug development projects ◦ Technology-savvy, integrate data ◦ Pharma CRO academia ◦ Management/leadership Behaviors ◦ Team player ◦ “Leadership” ◦ Problem solver, critical thinker ◦ Proactive ◦ Communication skills ◦ Inquisitive ◦ Adaptive
Flexibility Team player with broad skills and interests How are these influences changing pathology? - genomics, paraprofessionals, automated slide reading, 3R’s, offshoring, …
Widespread tightening of science/R&D budgets across federal agencies Pressure on basic science and bench pathology roles More emphasis on translational scientist and advisor roles Traditional pathology skills important, bridge skills critical ◦ Examples: Toxicology, Molecular biology/Biomarkers, Computational biology/Informatics
Pharma Tox. Pathology: In-depth Tox Path knowledge of a drug class or target GLP Lab Animal Veterinarian: Team effort to have animals & facility for tox studies Drug Program Leader: Team effort to move a novel compound to clinical trials CRO Pathology: In-depth Tox Path knowledge of spontaneous vs. test article findings International: Understanding how to work & teach in China & India Society of Tox Path: Source of continuous learning and consortium building
201220112010200920082007 Net Income Corp. A3525(380)37(596)104 Corp. B4105(32)100205196 200620052004200320022001 Net Income Corp. A826832183426 Corp. B154140112836748
Your consent to our cookies if you continue to use this website.